Association of time-to-treatment with prognosis in pneumocystis pneumonia among immunocompromised patients without HIV infection: a multi-center, retrospective observational cohort study

Abstract Background Pneumocystis jirovecii pneumonia (PCP) in non-human immunodeficiency virus (HIV) patients is associated with high morbidity and mortality. Although prior studies have linked delayed treatment to worse outcomes, they are often limited by small sample sizes and inadequate adjustmen...

Full description

Saved in:
Bibliographic Details
Main Authors: Haruka Fujioka, Hiroki Matsui, Yuya Homma, Tatsuya Nagai, Ayumu Otsuki, Hiroyuki Ito, Shinichiro Ohmura, Toshiaki Miyamoto, Daisuke Shichi, Watari Tomohisa, Yoshihito Otsuka, Kei Nakashima
Format: Article
Language:English
Published: BMC 2025-04-01
Series:BMC Infectious Diseases
Subjects:
Online Access:https://doi.org/10.1186/s12879-025-10933-3
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850206579683491840
author Haruka Fujioka
Hiroki Matsui
Yuya Homma
Tatsuya Nagai
Ayumu Otsuki
Hiroyuki Ito
Shinichiro Ohmura
Toshiaki Miyamoto
Daisuke Shichi
Watari Tomohisa
Yoshihito Otsuka
Kei Nakashima
author_facet Haruka Fujioka
Hiroki Matsui
Yuya Homma
Tatsuya Nagai
Ayumu Otsuki
Hiroyuki Ito
Shinichiro Ohmura
Toshiaki Miyamoto
Daisuke Shichi
Watari Tomohisa
Yoshihito Otsuka
Kei Nakashima
author_sort Haruka Fujioka
collection DOAJ
description Abstract Background Pneumocystis jirovecii pneumonia (PCP) in non-human immunodeficiency virus (HIV) patients is associated with high morbidity and mortality. Although prior studies have linked delayed treatment to worse outcomes, they are often limited by small sample sizes and inadequate adjustment for confounders. Therefore, we evaluated whether early treatment after hospital admission improves mortality in non-HIV PCP, adjusting for patient characteristics. Methods This multi-center, retrospective, observational cohort study included non-HIV PCP patients treated between January 2006 and March 2021 at three institutions. Participants were divided into the early treatment (initiated within 2 days) and late treatment (initiated between days 3 and 7) groups. The primary endpoint was 30-day mortality, and the secondary endpoints were 180-day mortality. Propensity score weighting was used to adjust for patient background. Results Ninety-four patients in the early treatment group and 43 in the late treatment group were evaluated. The average time-to-treatment for the early and late treatment groups was 0.13 days and 3.63 days, respectively. After adjusting for patient characteristics, there were no significant differences in 30-day mortality (14.0% vs. 8.2%, p = 0.307) or 180-day mortality (21.5% vs. 17.7%, p = 0.600) between the early and late treatment groups. In a subgroup analysis of cases requiring oxygen supplementation, 30-day and 180-day mortality also showed no significant differences between the two groups. Conclusion This study emphasizes the importance of accurate diagnosis and tailored management based on disease severity rather than immediate empirical treatment, as early treatment initiation was not significantly associated with 30-day or 180-day mortality in non-HIV PCP.
format Article
id doaj-art-5d9155133bd846358074ec503b52da02
institution OA Journals
issn 1471-2334
language English
publishDate 2025-04-01
publisher BMC
record_format Article
series BMC Infectious Diseases
spelling doaj-art-5d9155133bd846358074ec503b52da022025-08-20T02:10:46ZengBMCBMC Infectious Diseases1471-23342025-04-0125111010.1186/s12879-025-10933-3Association of time-to-treatment with prognosis in pneumocystis pneumonia among immunocompromised patients without HIV infection: a multi-center, retrospective observational cohort studyHaruka Fujioka0Hiroki Matsui1Yuya Homma2Tatsuya Nagai3Ayumu Otsuki4Hiroyuki Ito5Shinichiro Ohmura6Toshiaki Miyamoto7Daisuke Shichi8Watari Tomohisa9Yoshihito Otsuka10Kei Nakashima11Department of Pulmonology, Kameda Medical CenterDepartment of Clinical Epidemiology and Health Economics, School of Public Health, The University of TokyoDepartment of Pulmonology, Kameda Medical CenterDepartment of Pulmonology, Kameda Medical CenterDepartment of Pulmonology, Kameda Medical CenterDepartment of Pulmonology, Kameda Medical CenterDepartment of Rheumatology, Seirei Hamamatsu General HospitalDepartment of Rheumatology, Seirei Hamamatsu General HospitalDepartment of Infection and Rheumatology, Seirei Mikatahara General HospitalDepartment of Clinical Laboratory, Kameda Medical CenterDepartment of Clinical Laboratory, Kameda Medical CenterDepartment of Pulmonology, Kameda Medical CenterAbstract Background Pneumocystis jirovecii pneumonia (PCP) in non-human immunodeficiency virus (HIV) patients is associated with high morbidity and mortality. Although prior studies have linked delayed treatment to worse outcomes, they are often limited by small sample sizes and inadequate adjustment for confounders. Therefore, we evaluated whether early treatment after hospital admission improves mortality in non-HIV PCP, adjusting for patient characteristics. Methods This multi-center, retrospective, observational cohort study included non-HIV PCP patients treated between January 2006 and March 2021 at three institutions. Participants were divided into the early treatment (initiated within 2 days) and late treatment (initiated between days 3 and 7) groups. The primary endpoint was 30-day mortality, and the secondary endpoints were 180-day mortality. Propensity score weighting was used to adjust for patient background. Results Ninety-four patients in the early treatment group and 43 in the late treatment group were evaluated. The average time-to-treatment for the early and late treatment groups was 0.13 days and 3.63 days, respectively. After adjusting for patient characteristics, there were no significant differences in 30-day mortality (14.0% vs. 8.2%, p = 0.307) or 180-day mortality (21.5% vs. 17.7%, p = 0.600) between the early and late treatment groups. In a subgroup analysis of cases requiring oxygen supplementation, 30-day and 180-day mortality also showed no significant differences between the two groups. Conclusion This study emphasizes the importance of accurate diagnosis and tailored management based on disease severity rather than immediate empirical treatment, as early treatment initiation was not significantly associated with 30-day or 180-day mortality in non-HIV PCP.https://doi.org/10.1186/s12879-025-10933-3Non-human immunodeficiency virus-infected patientPneumocystis pneumoniaPrognosisTime-to-treatment
spellingShingle Haruka Fujioka
Hiroki Matsui
Yuya Homma
Tatsuya Nagai
Ayumu Otsuki
Hiroyuki Ito
Shinichiro Ohmura
Toshiaki Miyamoto
Daisuke Shichi
Watari Tomohisa
Yoshihito Otsuka
Kei Nakashima
Association of time-to-treatment with prognosis in pneumocystis pneumonia among immunocompromised patients without HIV infection: a multi-center, retrospective observational cohort study
BMC Infectious Diseases
Non-human immunodeficiency virus-infected patient
Pneumocystis pneumonia
Prognosis
Time-to-treatment
title Association of time-to-treatment with prognosis in pneumocystis pneumonia among immunocompromised patients without HIV infection: a multi-center, retrospective observational cohort study
title_full Association of time-to-treatment with prognosis in pneumocystis pneumonia among immunocompromised patients without HIV infection: a multi-center, retrospective observational cohort study
title_fullStr Association of time-to-treatment with prognosis in pneumocystis pneumonia among immunocompromised patients without HIV infection: a multi-center, retrospective observational cohort study
title_full_unstemmed Association of time-to-treatment with prognosis in pneumocystis pneumonia among immunocompromised patients without HIV infection: a multi-center, retrospective observational cohort study
title_short Association of time-to-treatment with prognosis in pneumocystis pneumonia among immunocompromised patients without HIV infection: a multi-center, retrospective observational cohort study
title_sort association of time to treatment with prognosis in pneumocystis pneumonia among immunocompromised patients without hiv infection a multi center retrospective observational cohort study
topic Non-human immunodeficiency virus-infected patient
Pneumocystis pneumonia
Prognosis
Time-to-treatment
url https://doi.org/10.1186/s12879-025-10933-3
work_keys_str_mv AT harukafujioka associationoftimetotreatmentwithprognosisinpneumocystispneumoniaamongimmunocompromisedpatientswithouthivinfectionamulticenterretrospectiveobservationalcohortstudy
AT hirokimatsui associationoftimetotreatmentwithprognosisinpneumocystispneumoniaamongimmunocompromisedpatientswithouthivinfectionamulticenterretrospectiveobservationalcohortstudy
AT yuyahomma associationoftimetotreatmentwithprognosisinpneumocystispneumoniaamongimmunocompromisedpatientswithouthivinfectionamulticenterretrospectiveobservationalcohortstudy
AT tatsuyanagai associationoftimetotreatmentwithprognosisinpneumocystispneumoniaamongimmunocompromisedpatientswithouthivinfectionamulticenterretrospectiveobservationalcohortstudy
AT ayumuotsuki associationoftimetotreatmentwithprognosisinpneumocystispneumoniaamongimmunocompromisedpatientswithouthivinfectionamulticenterretrospectiveobservationalcohortstudy
AT hiroyukiito associationoftimetotreatmentwithprognosisinpneumocystispneumoniaamongimmunocompromisedpatientswithouthivinfectionamulticenterretrospectiveobservationalcohortstudy
AT shinichiroohmura associationoftimetotreatmentwithprognosisinpneumocystispneumoniaamongimmunocompromisedpatientswithouthivinfectionamulticenterretrospectiveobservationalcohortstudy
AT toshiakimiyamoto associationoftimetotreatmentwithprognosisinpneumocystispneumoniaamongimmunocompromisedpatientswithouthivinfectionamulticenterretrospectiveobservationalcohortstudy
AT daisukeshichi associationoftimetotreatmentwithprognosisinpneumocystispneumoniaamongimmunocompromisedpatientswithouthivinfectionamulticenterretrospectiveobservationalcohortstudy
AT wataritomohisa associationoftimetotreatmentwithprognosisinpneumocystispneumoniaamongimmunocompromisedpatientswithouthivinfectionamulticenterretrospectiveobservationalcohortstudy
AT yoshihitootsuka associationoftimetotreatmentwithprognosisinpneumocystispneumoniaamongimmunocompromisedpatientswithouthivinfectionamulticenterretrospectiveobservationalcohortstudy
AT keinakashima associationoftimetotreatmentwithprognosisinpneumocystispneumoniaamongimmunocompromisedpatientswithouthivinfectionamulticenterretrospectiveobservationalcohortstudy